Ascendis Pharma (NASDAQ:ASND) has officially commenced the commercial launch of YUVIWEL® (navepegritide) in the United States, marking the availability of the first once-weekly treatment for pediatric patients with achondroplasia.
Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.
Lifezone Metals (NYSE:LZM) has announced the first successful production of platinum, palladium, and rhodium from U.S.-sourced spent automotive catalytic converters, marking a technical milestone for its proprietary Hydromet Technology.
Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, has reached a critical milestone in its international commercialization roadmap, receiving regulatory approval on April 7, 2026, to begin "by-invite" autonomous rides in Singapore.
Pershing Square, led by billionaire investor Bill Ackman, has proposed a transformative merger between its acquisition vehicle and Universal Music Group (UMG) to relocate the world’s largest music label’s primary listing to the New York Stock Exchange.
Organogenesis Holdings (NASDAQ:ORGO), a leader in regenerative medicine, has announced positive topline results from a prospective, multi-center randomized controlled trial (RCT) evaluating PuraPly AM for the treatment of diabetic foot ulcers (DFUs).
Telix Pharmaceuticals (NASDAQ:TLX), a global leader in radiopharmaceutical precision medicine, has reported Q1 2026 group revenue of $230 million, representing a 24% increase over the same period last year and an 11% sequential rise from the previous quarter.
Deere & Company (NYSE:DE) has reached a definitive agreement to resolve a consolidated multidistrict "right to repair" lawsuit, agreeing to pay $99 million into a class settlement fund for eligible farmers and ranchers.
Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines, has reported net sales of $30.3 million for its flagship product, Ryoncil (remestemcel-L-rknd), for the third fiscal quarter ended March 31, 2026.
Worldcoin fell to around $0.24 after a New Yorker investigation raised fresh concerns about founder Sam Altman’s credibility.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
